Last updated: March 2026
Oxiracetam is a water-soluble AMPA and NMDA receptor modulator with a mild stimulant quality that sets it apart from other racetams. Users and researchers consistently note improvements in logical reasoning, mathematical thinking, and sustained attention — making it a popular choice for demanding cognitive work.
Oxiracetam acts as a positive allosteric modulator of AMPA-type glutamate receptors and enhances NMDA receptor activity. This glutamatergic potentiation underlies its effects on long-term potentiation (LTP), the cellular basis of learning and memory. Its mild stimulant quality likely stems from increased catecholaminergic tone as a downstream effect of glutamate modulation.
Oxiracetam acts as a positive allosteric modulator of AMPA receptors — the fast-acting glutamate receptors responsible for rapid synaptic transmission. By slowing AMPA receptor desensitization, it increases and prolongs excitatory signaling. This is the primary mechanism shared with aniracetam and other ampakines, supporting enhanced LTP induction.
Unlike piracetam (which has minimal direct receptor binding), oxiracetam also modulates NMDA receptors — the "coincidence detectors" of the brain that gate LTP. Enhanced NMDA signaling makes it easier for synapses to strengthen during learning. This dual AMPA/NMDA action may explain oxiracetam's superior potency vs piracetam.
Like other racetams, oxiracetam enhances high-affinity choline uptake (HACU) in cortical and hippocampal tissue. This increases the availability of choline for acetylcholine synthesis. Supplementing with Alpha-GPC or CDP-choline when using oxiracetam can prevent racetam headaches and may enhance effects through synergistic cholinergic-glutamatergic interaction.
Oxiracetam produces mild stimulant-like effects not commonly seen with piracetam. This is thought to reflect downstream increases in dopamine and norepinephrine release secondary to glutamate upregulation. Unlike amphetamines, this effect has no direct catecholamine-releasing mechanism — it is a consequence of enhanced glutamatergic drive, making it milder and less habit-forming.
Clinical and preclinical data on oxiracetam's cognitive effects. Most human trials were conducted in patients with vascular dementia, Alzheimer's disease, or mild cognitive impairment (MCI) in the 1980s-1990s.
Stack oxiracetam with a choline source and consider a safe caffeine alternative on demanding days.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. It is not medical advice. Oxiracetam is not FDA-approved for any indication and is sold as a research compound. Always consult a qualified healthcare provider before use. Do not combine with stimulant medications without medical supervision.